Asceneuron

0 followers


Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Employees

11-50

Links

Org chart

Barbara Angehrn Pavik
Chief Executive Officer

Barbara Angehrn Pavik

Collapse
Sandra Millet
Head Of Operations
Matthew Foy
Investor
Eric Yuen
Scientific Advisory Board Member
Andrin Cerletti
Head Of Business Development
Henrijette Richter
Board Member
Ruhi Ahmed
SVP & Head of Regulatory Affairs
Bruno Permanne
Senior Director & Head of Preclinical Development
Colin Kahrs
Head of Intellectual Property